Pharmafile Logo

Fresenius Kabi Oncology

- PMLiVE

Janssen’s Tecvayli granted FDA approval for multiple myeloma

A phase 2 study demonstrated an overall response rate of 61.8% in Tecvayli-treated patients

- PMLiVE

ICR study reveals how cancers can evolve without relying on DNA mutations

The researchers found that epigenetic changes play a key role in how cancers adapt and evolve

Springer Nature Oncologists survey report 202

[Free Report] The What, How, and When of creating content for oncologists

Create content marketing that really engages healthcare professionals.

Springer Nature

- PMLiVE

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

Both trials showed significant improvement in progression-free survival

- PMLiVE

Gilead’s latest Biktarvy data offers hope to HIV patients

The data was shared at the 30th International Congress on Drug Therapy in HIV Infection

- PMLiVE

ICR study raises possibility of predicting drug resistance in advance

The researchers found that stomach cancers could develop resistance to ATR inhibitors

Full Panel Discussion: Closing The Gaps In Patient-Centricity

On 11th September, the Medscape team came together at the Eiffel Tower for an exciting event attended by expert faculty, patient advocates and more than a hundred supporters of our...

Medscape Education Global

- PMLiVE

Kite and Refuge Biotechnologies join to develop potential treatments for blood cancer

The agreement bolsters Kite’s expertise in synthetic biology for oncology

- PMLiVE

ICR research shows blood tests could help guide the treatment for children’s cancer

Using liquid biopsies to monitor patients could determine how well treatment is working

- PMLiVE

Medscape Medical Affairs are PMEA Finalists in Three Categories

The Pharmaceutical Market Excellence Awards (PMEA) have announced that Medscape Medical Affairs is a finalist in their 2022 awards for their entry Transatlantic Exchanges: Driving Therapeutic Innovation in Oncology for...

Medscape Medical Affairs

- PMLiVE

Gilead and MacroGenics enter $1.7bn oncology partnership

The collaboration will focus on developing bispecific antibodies

- PMLiVE

Novo Nordisk completes acquisition of Forma Therapeutics in deal worth $1.1bn

The acquisition includes a pipeline of haemoglobinopathies including etavopivat

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links